NHC Key Laboratory of Pulmonary Diseases, Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Immunol. 2020 Aug 28;11:2024. doi: 10.3389/fimmu.2020.02024. eCollection 2020.
Lung cancer represents a fatal condition that has the highest morbidity and mortality among malignancies. The currently available treatments fall short of improving the survival and quality of life of late-stage lung cancer patients. Extracellular vesicles (EVs) secreted by tumors or immune cells transport proteins, lipids, and nucleic acids to other cells, thereby mediating immune regulation in the tumor microenvironment. The cargo carried by EVs vary by cellular state or extracellular milieu. So far, multiple studies have suggested that EVs from lung tumor cells (TEVs) or immune cells promote tumor progression mainly through suppressing antitumor immunity. However, modified or engineered EVs can be used as vaccines to elicit antitumor immunity. In addition, blocking the function of immunosuppressive EVs and using EVs carrying immunogenic medicine or EVs from certain immune cells also shows great potential in lung cancer treatment. To provide information for future studies on the role of EVs in lung cancer immunity, this review focus on the immunoregulatory role of EVs and associated treatment applications in lung cancer.
肺癌是一种致命的疾病,在恶性肿瘤中发病率和死亡率最高。目前可用的治疗方法未能改善晚期肺癌患者的生存率和生活质量。肿瘤细胞或免疫细胞分泌的细胞外囊泡(EVs)将蛋白质、脂质和核酸运输到其他细胞,从而调节肿瘤微环境中的免疫调节。EV 所携带的货物因细胞状态或细胞外环境而异。迄今为止,多项研究表明,来自肺肿瘤细胞(TEVs)或免疫细胞的 EVs 主要通过抑制抗肿瘤免疫来促进肿瘤进展。然而,经过修饰或工程化的 EV 可作为疫苗来引发抗肿瘤免疫。此外,阻断免疫抑制性 EV 的功能并使用携带免疫原性药物的 EV 或来自某些免疫细胞的 EV,在肺癌治疗中也显示出巨大的潜力。为了为 EV 在肺癌免疫中的作用的未来研究提供信息,本综述重点关注 EV 的免疫调节作用及其在肺癌中的相关治疗应用。